Spyre Therapeutics, Inc.
SYRE
$23.78
-$0.68-2.78%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 526.58M | 564.82M | 603.09M | 414.23M | 426.00M |
| Total Receivables | 3.50M | 3.40M | -- | 1.70M | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.75M | 1.55M | 5.39M | 5.15M | 9.74M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 538.83M | 569.77M | 608.47M | 421.08M | 435.74M |
|
|
|||||
| Total Current Assets | 538.83M | 569.77M | 608.47M | 421.08M | 435.74M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | 10.00K | 10.00K | 10.00K | 331.00K |
| Total Assets | 538.83M | 569.78M | 608.48M | 421.09M | 436.07M |
|
|
|||||
| Total Accounts Payable | 3.71M | 3.69M | 666.00K | 5.17M | 3.23M |
| Total Accrued Expenses | 19.42M | 21.63M | 27.31M | 14.65M | 9.38M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 59.93M | 45.36M | 26.08M | 37.72M | 9.51M |
| Total Other Current Liabilities | 59.93M | 45.36M | 26.08M | 37.72M | 9.51M |
| Total Current Liabilities | 83.06M | 70.68M | 54.06M | 57.54M | 22.12M |
|
|
|||||
| Total Current Liabilities | 83.06M | 70.68M | 54.06M | 57.54M | 22.12M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | 16.49M | 36.62M | 36.16M | 39.56M |
| Total Liabilities | 83.06M | 87.17M | 90.68M | 93.70M | 61.68M |
|
|
|||||
| Common Stock & APIC | 1.35B | 1.34B | 1.33B | 1.09B | 1.07B |
| Retained Earnings | -1.05B | -1.02B | -972.43M | -916.14M | -847.11M |
| Treasury Stock & Other | 454.00K | 682.00K | 180.00K | 1.46M | -553.00K |
| Total Common Equity | 299.95M | 326.79M | 361.98M | 171.57M | 218.57M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
|
|
|||||
| Total Common Equity | 299.95M | 326.79M | 361.98M | 171.57M | 218.57M |
| Total Preferred Equity | 155.82M | 155.82M | 155.82M | 155.82M | 155.82M |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 455.77M | 482.61M | 517.80M | 327.39M | 374.39M |
|
|
|||||